<?xml version="1.0" encoding="UTF-8"?>
<p id="p0120">A randomized, double-blind, trial comprising 293 participants showed that COLD-fX, although well-tolerated, yet did not effectively reduce the length of ARI or antibiotic use in patients with ARI infected with chronic lymphocytic leukemia [
 <xref rid="bib109" ref-type="bibr">109</xref>]. Antibody titers and natural killer cell activities in 227 volunteers were significantly elevated in individuals who received 
 <italic>P. ginseng</italic> standardized extract (G115, 100 mg) once a day via the oral route for 12 weeks when compared with the placebo group [
 <xref rid="bib110" ref-type="bibr">110</xref>]. KRG effectively suppressed the duration and severity of ARI symptoms in 100 participants [
 <xref rid="bib111" ref-type="bibr">111</xref>]. A placebo-controlled, pilot study divided 45 participants randomly and administered a capsule (500 mg/cap and 3000 mg/day) of GS-3K8, GINST, or placebo. GS-3K8 and GINST prevented the development of ARI with no adverse drug reactions during the intervention and reduced symptom duration, with no drug intolerance [
 <xref rid="bib112" ref-type="bibr">112</xref>].
</p>
